ELAB Files S-1/A for Warrant Resale, Eyes $1.56M from Exercises

TL;DR

**ELAB's S-1/A is a red flag for dilution, as the company incentivizes warrant exercises while its stock trades below the new exercise price, signaling a desperate capital grab amidst a risky biotech pivot.**

AI Summary

PMGC Holdings Inc. (ELAB) filed an S-1/A on November 25, 2025, primarily for the resale of up to 236,543 shares of common stock underlying warrants. These warrants were issued as an inducement to existing warrant holders, reducing the exercise price from $11.27 to $7.0525 per share for existing warrants, and then issuing new warrants with an exercise price of $6.615 per share. The company will not receive proceeds from the selling shareholders' sales, but expects to receive approximately $1.56 million if all warrants are exercised for cash. ELAB completed the divestiture of its Elevai Skincare Inc. business on January 16, 2025, to focus on larger markets and biotechnology assets like Northstrive Biosciences Inc., which is developing EL-22, an engineered probiotic for muscle preservation during weight loss, having completed a Phase 1 trial in South Korea. The company also operates PMGC Capital LLC, Pacific Sun Packaging, Inc., and AGA Precision Systems LLC, and effected a 1:3.5 reverse stock split on September 2, 2025.

Why It Matters

This S-1/A filing signals PMGC Holdings' strategic pivot away from skincare towards biotechnology and diversified investments, potentially impacting future revenue streams and risk profiles. The inducement warrants and subsequent resale opportunity could introduce significant dilution for existing shareholders, while the potential $1.56 million in proceeds from warrant exercises offers a capital injection for ELAB's new ventures. For investors, the shift to biotech (Northstrive Biosciences' EL-22) places ELAB in a highly competitive and capital-intensive sector, contrasting with its previous consumer-focused business. The reverse stock split on September 2, 2025, aimed to boost share price, but the current trading price of $5.26 per share on November 25, 2025, below the new warrant exercise price of $6.615, suggests potential investor skepticism or market challenges.

Risk Assessment

Risk Level: high — The risk level is high due to several factors. The company's stock price of $5.26 per share on November 25, 2025, is below the new warrant exercise price of $6.615 per share, making cash exercise less attractive and potentially leading to further dilution if the stock rises. The divestiture of Elevai Skincare Inc. on January 16, 2025, and the pivot to early-stage biotechnology (EL-22 in Phase 1) and diversified investments introduce significant operational and market risks, as these sectors are highly competitive and capital-intensive with uncertain returns.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate ELAB's new business strategy and financial health. Given the stock's current trading price below the warrant exercise price, consider waiting for clearer signs of operational success in their new biotech and investment ventures before committing capital. Monitor the actual warrant exercise rates and the company's use of any resulting proceeds.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Executive Compensation

Key Numbers

• 236,543 — Shares of Common Stock (Maximum number of shares underlying warrants offered for resale by selling security holders)
• $11.27 — Original Warrant Exercise Price (Initial exercise price of existing warrants before inducement)
• $7.0525 — Reduced Warrant Exercise Price (Exercise price of existing warrants after inducement)
• $6.615 — New Warrant Exercise Price (Exercise price of the newly issued warrants)
• $1.56 million — Potential Proceeds (Aggregate proceeds if all new warrants are exercised for cash by selling shareholders)
• $5.26 — Common Stock Sale Price (Last reported sale price of ELAB Common Stock on November 25, 2025)
• 1:3.5 — Reverse Stock Split Ratio (Effected on September 2, 2025)
• January 16, 2025 — Divestiture Date (Date of completion of Elevai Skincare Inc. asset divestiture)
• Phase 1 — Clinical Trial Stage (Stage of EL-22 clinical development in South Korea)
• 4 — Non-provisional Patent Applications (Number of non-provisional patent applications filed by PMGC Holdings Inc. as of November 25, 2025)

Key Players & Entities

• PMGC Holdings Inc. (company) — Registrant and diversified holding company
• ELAB (company) — Ticker symbol for PMGC Holdings Inc.
• Northstrive Biosciences Inc. (company) — Wholly owned biopharmaceutical subsidiary developing EL-22
• PMGC Capital LLC (company) — Wholly owned multi-strategy investment firm subsidiary
• Pacific Sun Packaging, Inc. (company) — Wholly owned specialty packaging provider subsidiary
• AGA Precision Systems LLC (company) — Wholly owned specialized CNC machine shop subsidiary
• Elevai Skincare Inc. (company) — Divested business as of January 16, 2025
• Graydon Bensler (person) — Chief Executive Officer and Chief Financial Officer of PMGC Holdings Inc.
• Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for the registrant
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing

FAQ

Risk Factors

• Dilution from Warrant Exercise [medium — financial]: The resale of up to 236,543 shares underlying warrants, with a reduced exercise price of $7.0525 and new warrants at $6.615, could lead to significant dilution for existing shareholders. If all new warrants are exercised, the company expects to receive approximately $1.56 million, but this also increases the total number of outstanding shares.
• Dependence on Northstrive Biosciences [high — operational]: The company's strategic focus on biotechnology assets, particularly Northstrive Biosciences Inc. and its drug candidate EL-22, creates a concentration risk. The success of the company is now heavily reliant on the development and market acceptance of EL-22, which has only completed Phase 1 trials.
• Reverse Stock Split Impact [medium — financial]: The 1:3.5 reverse stock split effected on September 2, 2025, aims to increase the per-share price but can also signal underlying financial challenges or a need to meet exchange listing requirements. It may not address the fundamental business issues and could deter some investors.
• Divestiture of Elevai Skincare [medium — operational]: The divestiture of the Elevai Skincare Inc. business on January 16, 2025, indicates a strategic shift away from certain operations. While intended to focus on larger markets, it also means the company is exiting a revenue-generating segment, the impact of which needs careful monitoring.
• Biotechnology Market Volatility [high — market]: The biotechnology sector is inherently volatile, subject to significant regulatory hurdles, lengthy development cycles, and high failure rates. The success of Northstrive Biosciences' EL-22 is subject to these market dynamics and clinical trial outcomes.

Industry Context

PMGC Holdings Inc. is pivoting towards the biotechnology sector, specifically focusing on assets like Northstrive Biosciences Inc. This industry is characterized by high R&D costs, long development timelines, stringent regulatory oversight from bodies like the FDA, and significant competition from established pharmaceutical companies and emerging biotech firms. Success hinges on innovation, clinical trial outcomes, and intellectual property protection.

Regulatory Implications

The company's focus on biotechnology brings it under the purview of health regulatory bodies. The development of EL-22 will require adherence to strict FDA (or equivalent international) guidelines for clinical trials and eventual market approval. Any delays or failures in regulatory processes could significantly impact the company's valuation and prospects.

What Investors Should Do

1. Monitor Northstrive Biosciences' progress closely.
2. Assess the impact of warrant dilution.
3. Evaluate the strategic rationale behind the divestiture.
4. Consider the implications of the reverse stock split.

Key Dates

• 2025-01-16: Divestiture of Elevai Skincare Inc. — Marks a strategic shift for the company to focus on biotechnology assets and larger markets.
• 2025-09-02: 1:3.5 Reverse Stock Split — Aims to increase the per-share stock price and potentially meet exchange listing requirements.
• 2025-11-25: S-1/A Filing — Details the resale of shares underlying warrants and provides updated company information.

Glossary

S-1/A

An amended registration statement filed with the SEC, typically used when a company is going public or has previously filed an S-1 and needs to make changes. (This filing provides the latest details on the company's financial condition, business operations, and the proposed resale of shares.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) within a specified timeframe. (The filing concerns the resale of shares underlying warrants, with adjusted exercise prices, impacting potential dilution and future cash flow if exercised.)

Divestiture

The act of selling off or disposing of a business unit, subsidiary, or asset. (The company divested its Elevai Skincare business to refocus on its biotechnology assets.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them, effectively increasing the price per share. (PMGC Holdings Inc. implemented a 1:3.5 reverse stock split, which affects the share count and per-share metrics.)

Phase 1 Clinical Trial

The initial stage of testing a new drug or treatment in a small group of people to assess safety, determine a safe dosage range, and identify side effects. (EL-22, a key asset, has completed Phase 1 trials, indicating early-stage development and associated risks.)

Year-Over-Year Comparison

Information comparing key metrics to a previous year's filing is not available in the provided text. The S-1/A filing on November 25, 2025, focuses on the resale of shares underlying warrants and provides an update on the company's strategic shift post-divestiture of its skincare business. Key changes include the focus on biotechnology assets like Northstrive Biosciences and the implementation of a reverse stock split.

Key Financial Figures

• $0.0001 — 6,543 shares of common stock, par value $0.0001 per share ("Common Stock") issuable upo
• $11.27 — that initially had an exercise price of $11.27 per share to $7.0525 per share as an in
• $7.0525 — n exercise price of $11.27 per share to $7.0525 per share as an inducement to the exerc
• $6.615 — f the Warrants has an exercise price of $6.615 per share and will be exercisable at an
• $1.56 million — oceeds of an aggregate of approximately $1.56 million if the Selling Shareholders exercise al
• $5.26 — rted sale price of the Common Stock was $5.26 per share. On September 2, 2025, we e
• $548,000 — hase Price for the Purchased Assets was $548,000.00, payable at Closing as follows: (a)
• $350,000.00 — .00, payable at Closing as follows: (a) $350,000.00 to be used to satisfy and discharge Sel
• $28,000.00 — Small Business Administration loan; (b) $28,000.00 to be paid to Seller at Closing; and (c
• $170,000.00 — o be paid to Seller at Closing; and (c) $170,000.00 to be paid pursuant to a two-year promi

Filing Documents

• ea0266119-s1a2_pmgchold.htm (S-1/A) — 4440KB
• ea026611901ex5-1_pmgc.htm (EX-5.1) — 9KB
• ea026611901ex23-1_pmgc.htm (EX-23.1) — 2KB
• ea026611901ex23-2_pmgc.htm (EX-23.2) — 2KB
• image_001.jpg (GRAPHIC) — 14KB
• image_002.jpg (GRAPHIC) — 4KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-25-114958.txt ( ) — 19422KB
• elab-20250930.xsd (EX-101.SCH) — 130KB
• elab-20250930_cal.xml (EX-101.CAL) — 109KB
• elab-20250930_def.xml (EX-101.DEF) — 678KB
• elab-20250930_lab.xml (EX-101.LAB) — 1050KB
• elab-20250930_pre.xml (EX-101.PRE) — 713KB
• ea0266119-s1a2_pmgchold_htm.xml (XML) — 3372KB

RISK FACTORS

RISK FACTORS 23 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 30

USE OF PROCEEDS

USE OF PROCEEDS 31 MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS 31 PRIVATE PLACEMENT OF SECURITIES 32

MANAGEMENT'S DISCUSSION AND ANALYSIS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 33

BUSINESS

BUSINESS 58 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 83 MANAGEMENT 91

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 98 PRINCIPAL STOCKHOLDERS 115 SELLING SHAREHOLDERS 117

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 119 PLAN OF DISTRIBUTION 122 EXPERTS 124 LEGAL MATTERS 124 WHERE YOU CAN FIND MORE INFORMATION 124 INFORMATION INCORPORATED BY REFERENCE 125 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. We have not authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. i ABOUT THIS PROSPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise, all references to the "Company," "PMGC," the "registrant," "we," "our" or "us" in this prospectus mean PMGC Holdings Inc. and its wholly owned subsidiaries, PMGC Capital LLC, Northstrive Biosciences Inc. Pacific Sun Packaging, Inc., and AGA Precision Systems LLC; "year

View Full Filing

View this S-1/A filing on SEC EDGAR